Publicacións (159) Publicacións de PABLO AGUIAR FERNANDEZ

filter_list

2025

  1. A physiologically based pharmacokinetic model to describe [89Zr]Zr-DFO-Adalimumab specific activity after intravitreal administration to rats with endotoxin-induced uveitis

    International Journal of Pharmaceutics, Vol. 681

  2. Absence of MCJ/DnaJC15 promotes brown adipose tissue thermogenesis

    Nature communications, Vol. 16, Núm. 1, pp. 229

  3. Blood Progenitor Cell Mobilization Driven by TWEAK Promotes Neovascularization and Reduces Brain Damage in a Rat Model of Intracerebral Hemorrhage

    Antioxidants, Vol. 14, Núm. 5

  4. Delivery of monoclonal antibodies to the brain: the impact of nanocarrier structure

    Drug Delivery and Translational Research

  5. Design and characterization of intravitreal bevacizumab-loaded PLGA nanoparticles: pharmacokinetic and biodistribution impact

    Drug Delivery and Translational Research

  6. Frequency and Clinical Outcomes Associated with Tau Positron Emission Tomography Positivity

    JAMA

  7. Hypometabolism and atrophy patterns associated with Niemann-Pick type C

    EJNMMI Research, Vol. 15, Núm. 1

  8. Intracerebroventricular phospho-tau immunotherapy alleviates cortical phospho-tau burden and motor phenotype in a neuron-specific P301S tauopathy mouse

    Experimental Neurology, Vol. 391

  9. Intravitreal Administration of Adalimumab-Loaded Poly(Lactic-co-Glycolic Acid) Nanoparticles: Effects on Biodistribution and Pharmacokinetics

    Small Science

  10. Lecanemab approval in EU: what should we be ready for?– the EANM perspective

    European Journal of Nuclear Medicine and Molecular Imaging

  11. Mini-GRID therapy delivers optimised spatially fractionated radiation therapy using a flattening free filter accelerator

    Communications Medicine, Vol. 5, Núm. 1

  12. Neuroprotective effect of small extracellular vesicle-mediated targeting of AMPKα2 in cerebral ischemia

    Metabolism: Clinical and Experimental, Vol. 167

  13. PET biodistribution study of subcutaneous and intravenous administration of adalimumab in an inflammatory bowel disease model

    International Journal of Pharmaceutics, Vol. 669

  14. Procedure update and interpretation guide for the brain 18F-FDG PET study

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 44, Núm. 4

2024

  1. 18F-FDG positron emission tomography as a marker of disease activity and treatment response in ankylosing spondylitis and psoriatic arthritis

    Scientific Reports, Vol. 14, Núm. 1

  2. Biodistribution and pharmacokinetics of [89Zr]-anti-VEGF mAbs using PET in glioblastoma rat models

    International Journal of Pharmaceutics, Vol. 652

  3. Correction to: EANM perspectives for CZT SPECT in brain applications (European Journal of Nuclear Medicine and Molecular Imaging, (2024), 51, 12, (3680-3684), 10.1007/s00259-024-06788-6)

    European Journal of Nuclear Medicine and Molecular Imaging

  4. EANM perspectives for CZT SPECT in brain applications

    European Journal of Nuclear Medicine and Molecular Imaging

  5. Neuroimaging biomarkers in the biological definition of Parkinson’s disease and dementia with Lewy bodies – EANM position on current state, unmet needs and future perspectives

    European Journal of Nuclear Medicine and Molecular Imaging

  6. Partial volume correction in longitudinal tau PET studies: is it really needed?

    NeuroImage, Vol. 289